Literature DB >> 9066111

Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.

R A Bonomo1, S A Rudin, D M Shlaes.   

Abstract

The beta-lactam beta-lactamase inhibitor combinations (ampicillin/clavulanate, ampicillin/sulbactam, ticarcillin/clavulanate and piperacillin/tazobactam) were tested against selected inhibitor-resistant class A beta-lactamases of the TEM and OHIO-1 varieties. Minimum inhibitor concentrations (MIC) revealed that the Escherichia coli DH5 alpha transconjugate strains that possessed the OHIO-1 beta-lactamase, Met69Ile mutant of the OHIO-1 beta-lactamase, TEM-30 (Arg244Ser) and TEM-31 (Arg244Cys) beta-lactamase were most susceptible to piperacillin and piperacillin/tazobactam. Kinetic experiments with each beta-lactamase demonstrated that tazobactam was 10-25-fold more potent than clavulanate or sulbactam against TEM-30 and TEM-31 beta-lactamase. Tazobactam was also as effective as clavulanate against the Met69Ile mutant of the OHIO-1 beta-lactamase. Among the clinically available beta-lactams and beta-lactamase inhibitors, piperacillin/tazobactam appears to be the most potent combination against selected inhibitor-resistant strains of TEM and OHIO-1 beta-lactamase.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9066111     DOI： 10.1111/j.1574-6968.1997.tb10267.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN： 0378-1097            Impact factor:   2.742


  14 in total

1.  What's New in beta-lactamases?

Authors:  Patricia A. Bradford
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

Review 2.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  TEM-103/IRT-28 beta-lactamase, a new TEM variant produced by Escherichia coli BM4511.

Authors:  Rodrigo Alonso; Guy Gerbaud; Marc Galimand; Patrice Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit.

Authors:  Kim W Benner; Priya Prabhakaran; Autumn S Lowros
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

5.  Properties of mutant SHV-5 beta-lactamases constructed by substitution of isoleucine or valine for methionine at position 69.

Authors:  P Giakkoupi; V Miriagou; M Gazouli; E Tzelepi; N J Legakis; L S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 6.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

7.  A Structural Basis for 129 Xe Hyper-CEST Signal in TEM-1 β-Lactamase.

Authors:  Benjamin W Roose; Serge D Zemerov; Yanfei Wang; Marina A Kasimova; Vincenzo Carnevale; Ivan J Dmochowski
Journal:  Chemphyschem       Date:  2018-09-13       Impact factor: 3.102

Review 8.  Molecular Sensing with Host Systems for Hyperpolarized 129Xe.

Authors:  Jabadurai Jayapaul; Leif Schröder
Journal:  Molecules       Date:  2020-10-11       Impact factor: 4.411

Review 9.  Three decades of beta-lactamase inhibitors.

Authors:  Sarah M Drawz; Robert A Bonomo
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  Extended Spectrum beta-Lactamases among Gram-Negative Bacterial Isolates from Clinical Specimens in Three Major Hospitals in Northern Jordan.

Authors:  Raymond G Batchoun; Samer F Swedan; Abdullah M Shurman
Journal:  Int J Microbiol       Date:  2009-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.